1028481-90-4

Upstream product

• 1028481-54-0 (R)-4-((2S,6R)-6-(((2S,6R)-6-((E)-3-((2S,6S)-6-((2R,3R)-3-(benzyloxymethoxy)-2-(tert-butyldimethylsilyloxy)butyl)-2-methoxy-3-oxo-tetrahydro-2H-pyran-2-yl)-3-methylbut-1-enyl)-4-methylene-tetrahydro-2H-pyran-2-yl)methyl)-4-methylene-tetrahydro-2H-pyran-2-yl)-3-(4-methoxybenzyloxy)butanoic acid 
• 1028481-82-4 (R)-4-((2S,6R)-6-(((2S,6R)-6-((E)-3-((2S,6S)-6-((2R,3R)-3-(benzyloxymethoxy)-2-(tert-butyldimethylsilyloxy)butyl)-2-methoxy-3-oxo-tetrahydro-2H-pyran-2-yl)-3-methylbut-1-enyl)-4-methylene-tetrahydro-2H-pyran-2-yl)methyl)-4-methylene-tetrahydro-2H-pyran-2-yl)-3-(4-methoxybenzyloxy)butanal 
• 1028481-80-2 (2S,6S)-6-((2R,3R)-3-(benzyloxymethoxy)-2-(tert-butyldimethylsilyloxy)butyl)-2-((E)-4-((2R,6S)-6-(((2R,6S)-6-((S)-4-hydroxy-2-(4-methoxybenzyloxy)butyl)-4-methylene-tetrahydro-2H-pyran-2-yl)methyl)-4-methylene-tetrahydro-2H-pyran-2-yl)-2-methylbut-3-en-2-yl)-2-methoxy-dihydro-2H-pyran-3(4H)-one 
• 1028481-52-8 (2S,6S)-6-((2R,3R)-3-(benzyloxymethoxy)-2-(tert-butyldimethylsilyloxy)butyl)-2-((E)-4-((2R,6S)-6-(((2R,6S)-6-((S)-4-(tert-butyldiphenylsilyloxy)-2-(4-methoxybenzyloxy)butyl)-4-methylene-tetrahydro-2H-pyran-2-yl)methyl)-4-methylene-tetrahydro-2H-pyran-2-yl)-2-methylbut-3-en-2-yl)-2-methoxy-dihydro-2H-pyran-3(4H)-one 
• 1028481-50-6 (E)-4-((2S,6S)-6-((2R,3R)-3-(benzyloxymethoxy)-2-(tert-butyldimethylsilyloxy)butyl)-2-methoxy-3-oxo-tetrahydro-2H-pyran-2-yl)-4-methylpent-2-enal 
• 1028481-78-8 S-ethyl (E)-4-((2S,6S)-6-((2R,3R)-3-(benzyloxymethoxy)-2-(4-methoxybenzyloxy)butyl)-2-(tert-butyldimethylsilyloxy)butyl-2-methoxy-3-oxo-tetrahydro-2H-pyran-2-yl)-4-methylpent-2-enethioate 
• 1028481-76-6 S-ethyl (E)-4-((2S,6S)-6-((2R,3R)-3-(benzyloxymethoxy)-2-(4-methoxybenzyloxy)butyl)-2-methoxy-3-oxo-tetrahydro-2H-pyran-2-yl)-4-methylpent-2-enethioate 
• 854931-23-0 (E)-4-{(S)-6-[(2R,3R)-3-Benzyloxymethoxy-2-(4-methoxy-benzyloxy)-butyl]-5,6-dihydro-4H-pyran-2-yl}-4-methyl-pent-2-enethioic acid S-ethyl ester 
• 1028481-48-2 (S)-1-((2R,6S)-6-((S)-4-(tert-butyldiphenylsilyloxy)-2-(4-methoxybenzyloxy)butyl)-4-methylenetetrahydro-2H-pyran-2-yl)-4-((trimethylsilyl)methyl)pent-4-en-2-ol 
• 1028481-73-3 ethyl (R)-4-((2R,6S)-6-((S)-4-(tert-butyldiphenylsilyloxy)-2-(4-methoxybenzyloxy)butyl)-4-methylenetetrahydro-2H-pyran-2-yl)-3-(trimethylsilyloxy)butanoate 
• 1028481-69-7 ethyl (R)-4-((2R,6S)-6-((S)-4-(hydroxy)-2-(4-methoxybenzyloxy)butyl)-4-methylenetetrahydro-2H-pyran-2-yl)-3-hydroxy-butanoate 
• 922-68-9 Methyl glyoxylate 
• 1028481-56-2 17-{(1S)-1-[(phenylmethoxy)methoxy]ethyl}(11S,17S,1R,3R,7R,21R,23R)-11-methoxy-10,10-dimethyl-5,25-dimethylene-18,27,28,29-tetraoxa-21-(4-methoxybenzyloxy)tetracyclo[21.3.1.1^3,7.1^17,15]nonacosa-8-ene-12,19-dione 

Downstream Products

• 1028481-58-4 methyl 2-(11-methoxy-10,10-dimethyl-5,25-dimethylene-12,19-dioxo-17-{[(phenylmethoxy)methoxy]ethyl}-21-(4-methoxybenzyloxy)-18,27,28,29-tetraoxatetracyclo[21.3.1.1^3,7.1^11,15]nonacosa-8-en-13-ylidene) acetate 
• 1028481-60-8 C₄₁H₅₄O₁₂ 

Relevant academic research and scientific papers

BRYOSTATIN ANALOGS AND USE THEREOF AS ANTIVIRAL AGENTS

Described herein are tricyclic macrolactones. The macrolactones have a high binding affinity for PKC. The compounds described herein can be used in a number of therapeutic applications including the treatment or prevention of viral infection. Also described herein are methods for producing macrolactones. The methods permit the high-yield synthesis of macrolactones in a low number of steps and with a high degree of substitution and specificity.

Convergent assembly of highly potent analogues of bryostatin 1 via pyran annulation: Bryostatin look-alikes that mimic phorbol ester function

Highly potent bryostatin analogues which contain the complete bryostatin core structure have been synthesized using a pyran annulation approach as a key strategic element. The A ring pyran was assembled using a pyran annulation reaction between a C1-C8 hydroxy allylsilane and an aldehyde comprising C9-C13. This pyran was transformed to a new hydroxy allylsilane and then coupled with a preformed C ring aldehyde subunit in a second pyran annulation, with concomitant formation of the B ring. This tricyclic intermediate was elaborated to bryostatin analogues which displayed nanomolar to subnanomolar affinity for PKC, but displayed properties indistinguishable from a phorbol ester in a proliferation/attachment assay. Copyright